A PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION COMPRISING 4-AMINO-5-FLUORO-3-[6-(4-METHYLPIPERAZIN-1-YL)-1H-BENZIMIDAZOL-2-YL]-1H-QUINOLIN-2-ONE MONOLACTATE MONOHYDRATE, A FILLER IN AN AMOUNT OF 15 TO 70% BY WEIGHT, A DISINTEGRANT IN AN AMOUNT OF LESS THAN 15% BY WEIGHT, A GLIDANT AND/OR A LUBRICANT IN AN AMOUNT OF 0.1 TO 10% BY WEIGHT WHEREIN THE AMOUNTS BY WEIGHT ARE BASED ON THE TOTAL WEIGHT OF THE COMPOSITION.